Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diffuse Large B-Cell Lymphoma.

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified B-Cell Lymphomas.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

Retifanlimab is under clinical development by Incyte and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

KH-903 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase II for Metastatic Colorectal Cancer.

Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Marginal Zone B-cell Lymphoma.

Tinostamustine is under clinical development by Mundipharma EDO and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer.

Belrestotug is under clinical development by iTeos Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

MCLA-145 is under clinical development by Merus and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Gammora is under clinical development by Zion Medical and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).